Literature DB >> 20575982

Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia.

Vincenzo Favilla1, Sebastiano Cimino, Tommaso Castelli, Massimo Madonia, Ignazio Barbagallo, Giuseppe Morgia.   

Abstract

OBJECTIVES: To investigate a possible association between the severity of lower urinary tract symptoms (LUTS) and the serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia (BPH) that underwent surgery for severe benign prostatic obstruction. PATIENTS AND METHODS: In all, 127 selected men with symptomatic BPH attending our urology clinic were recruited. The clinical conditions of BPH were assessed by digital rectal examination, serum prostate-specific antigen (PSA) determination, International Prostate Symptom Score (IPSS), transrectal ultrasonography and maximum urinary flow rate (Q(max) ) value at uroflussimetry. Before surgery, we measured the serum concentrations of total testosterone (TT) and free testosterone (FT), oestradiol, prolactin, luteinizing hormone and follicle-stimulating hormone. We excluded men with endocrine diseases, those with prostate disease who were receiving antiandrogen therapy and those with psychological diseases. The relationships between the IPSS score and serum sex hormone levels were determined.
RESULTS: The final study population consisted of 122 men (mean age of 70.66 years), as five were excluded (three due to incomplete evaluation and two who were diagnosed with prostate cancer). On statistical analysis, the total IPSS was significantly associated with age (r= 0.405, P < 0.001) and TT (r= 0.298, P= 0.020) but not with FT or the serum levels of the other sex hormones. The serum levels of testosterone and IPSS did not correlate with prostate volume and Q(max) . PSA level and age correlated with prostate volume (r= 0.394, P < 0.001; r = 0.374, P < 0.001, respectively). We distinguished two subgroups of patients: the first group of 40 men with an IPSS of <19 and the second group of 82 with an IPSS of >19, and we evaluated the median levels of TT in each group. There was an increased risk of LUTS in men with a greater serum concentration of TT (P= 0.042), although the mean TT level was in the normal range.
CONCLUSIONS: In the present study, the severity of LUTS was associated with age and serum levels of TT but only age correlated with the measures of BPH, especially prostate volume. The potential effects of testosterone on LUTS may well be indirect. Additional large studies are needed to confirm these preliminary results.
© 2010 THE AUTHORS. JOURNAL COMPILATION © 2010 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20575982     DOI: 10.1111/j.1464-410X.2010.09459.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  16 in total

1.  Risk factors of sexual dysfunction after transurethral resection of the prostate (TURP): a 12 months follow-up.

Authors:  V Favilla; S Cimino; C Salamone; E Fragalà; M Madonia; R Condorelli; S La Vignera; L Mongioì; F Pirozzi Farina; G I Russo; G Morgia
Journal:  J Endocrinol Invest       Date:  2013-12       Impact factor: 4.256

2.  Relationship between non-alcoholic fatty liver disease and benign prostatic hyperplasia/lower urinary tract symptoms: new insights from an Italian cross-sectional study.

Authors:  Giorgio Ivan Russo; Sebastiano Cimino; Eugenia Fragalà; Salvatore Privitera; Sandro La Vignera; Rosita Condorelli; Aldo E Calogero; Mario Chisari; Tommaso Castelli; Vincenzo Favilla; Giuseppe Morgia
Journal:  World J Urol       Date:  2014-09-05       Impact factor: 4.226

3.  Heme oxygenase levels and metaflammation in benign prostatic hyperplasia patients.

Authors:  Giorgio Ivan Russo; Luca Vanella; Tommaso Castelli; Sebastiano Cimino; Giulio Reale; Daniele Urzì; Giovanni Li Volti; Mauro Gacci; Marco Carini; Fabio Motta; Rosario Caltabiano; Lidia Puzzo; Valeria Sorrenti; Giuseppe Morgia
Journal:  World J Urol       Date:  2015-11-30       Impact factor: 4.226

4.  Prevalence and risk factors for erectile dysfunction and lower urinary tract symptoms in Russian Federation men: analysis from a national population-based multicenter study.

Authors:  I A Korneyev; T A Alexeeva; S H Al-Shukri; A N Bernikov; A A Erkovich; A A Kamalov; M I Kogan; V N Pavlov; V N Zhuravlev; D Y Pushkar
Journal:  Int J Impot Res       Date:  2016-02-11       Impact factor: 2.896

5.  Serum prostate-specific antigen as a predictor of prostate volume and lower urinary tract symptoms in a community-based cohort: a large-scale Korean screening study.

Authors:  Dong Soo Park; Jong Jin Oh; Jae Yup Hong; Young Kwon Hong; Don Kyung Choi; In Hyuck Gong; Jin Ho Hwang; Sung Won Kwon
Journal:  Asian J Androl       Date:  2013-01-28       Impact factor: 3.285

6.  Predicting erectile dysfunction in sexually active patients seeking prostate health screening: proposal for a multivariable risk stratification.

Authors:  V Favilla; G I Russo; G Reale; S Leone; T Castelli; S La Vignera; R A Condorelli; A E Calogero; S Cimino; G Morgia
Journal:  Int J Impot Res       Date:  2015-07-30       Impact factor: 2.896

7.  Testosterone replacement therapy and prostate health.

Authors:  A Scott Polackwich; Kevin A Ostrowski; Jason C Hedges
Journal:  Curr Urol Rep       Date:  2012-12       Impact factor: 3.092

Review 8.  Testosterone and benign prostatic hyperplasia.

Authors:  Thomas R Jarvis; Bilal Chughtai; Steven A Kaplan
Journal:  Asian J Androl       Date:  2015 Mar-Apr       Impact factor: 3.285

9.  Metabolic syndrome and benign prostatic hyperplasia: association or coincidence?

Authors:  Aleksandra Rył; Iwona Rotter; Tomasz Miazgowski; Marcin Słojewski; Barbara Dołęgowska; Anna Lubkowska; Maria Laszczyńska
Journal:  Diabetol Metab Syndr       Date:  2015-10-29       Impact factor: 3.320

10.  Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis.

Authors:  M Kirby; C Chapple; G Jackson; I Eardley; D Edwards; G Hackett; D Ralph; J Rees; M Speakman; J Spinks; K Wylie
Journal:  Int J Clin Pract       Date:  2013-04-25       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.